definiens: within themeaning of the provisions of the Private Securities Litigation Reform Act of 1995 . You should be awarethat our actual results could differ materially from those contained in the forward - looking statements, which are basedon current market data and research ( including third party and POZEN sponsored market studies and reports),management ’s current expectations and are subject to a number of risks and uncertainties, including, but not limitedto, our inability to license our PA product candidates on terms and timing acceptable to us, our inability to file a newdrug application with the FDA for our PA product candidates in the timeframe we anticipate, our failure to successfullycommercialize our product candidates ; costs and delays in the development and/or FDA approval of our productcandidates, including as a result of the need to conduct additional studies, or the failure to obtain such approval of ourproduct candidates, including as a result of changes in regulatory standards or the regulatory environment during thedevelopment period of any of our product candidates ; uncertainties in clinical trial results or the timing of such trials, resulting in, among other things, an extension in the period over which we recognize deferred revenue or our failure toachieve milestones that would have provided us with revenue ; our inability to maintain or enter into, and the risksresulting from our dependence upon, collaboration or contractual arrangements necessary for the development, manufacture, commercialization, marketing, sales and distribution of any products, including our dependence onAstraZeneca for the sales and marketing of VIMOVO ® ; competitive factors ; our inability to protect our patents orproprietary rights and obtain necessary rights to third party patents and intellectual property to operate our business;our inability to operate our business without infringing the patents and proprietary rights of others ; general economicconditions ; the failure of any products to gain market acceptance ; our inability to obtain any additional requiredfinancing ; technological changes ; government regulation ; changes in industry practice ; and one - time events, includingthose discussed herein and in our Quarterly Report on Form 10 - Q for the period ended March 31, 2013 . We do notintend to update any of these factors or to publicly announce the results of any revisions to these forward - lookingstatements